Company

One.Bio

One.Bio develops natural oligosaccharides and tools to study their prebiotic and immunomodulatory effects.

About

Founded in 2019 in California, One.Bio develops oligosaccharides and a platform for studying their effects as prebiotics and immunomodulators. Its tools assess carbohydrate structure and interactions with bacteria, supporting research and product development. In December 2024, it raised USD 27 million in Series A funding led by Alpha Edison, with participation from Acre Venture Partners, Collaborative Fund, iSelect Fund Management, Skyviews Life Science, DSM-firmenich, E12 Ventures, Leaps by Bayer, Morado Ventures, and ReMy Ventures.

3Funding rounds

10Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in